Here are the 10-K annual reports from Silence Therapeutics Plc (SLN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SLN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLN filings page.
Silence Therapeutics plc is a UK-based biotechnology company developing short interfering RNA (siRNA) medicines using its mRNAi GOLD™ liver-targeted platform. Its lead rare disease program, divesiran (SLN124), is in a fully enrolled Phase 2 SANRECO trial for polycythemia vera, with topline results expected in the third quarter of 2026.
Cardiometabolic pipeline assets include zerlasiran (SLN360), a Phase 3–ready siRNA targeting Lp(a) for cardiovascular disease, SLN312 targeting ANGPTL3, SLN365 for cholesterol via GPR146, and SLN098 for obesity via INHBE, all designed for potent, infrequent subcutaneous dosing. The company believes existing cash, cash equivalents and anticipated milestone payments from current collaborations can fund operations into 2028.
Silence has collaboration histories with AstraZeneca and Hansoh. AstraZeneca advanced SLN312 into Phase 1 with multiple milestone payments but decided on March 4, 2026 not to pursue development beyond Phase 1, after which Silence will regain full global rights. Hansoh paid upfront and milestone amounts on three siRNA targets but elected in December 2024 not to continue development, leaving Silence with worldwide rights to those programs.